FXR agonists have been shown to have significant therapeutic effects on non-alcoholic fatty liver disease (NAFLD), and CAG can effectively activate FXR, reduce liver fibrosis, and decrease hepatocyte apoptosis. This evidence concerns the gene NR1H4 and Hepatic fibrosis.